A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and
safety of zanidatamab in combination with physician’s choice chemotherapy compared to
trastuzumab in combination with physician’s choice chemotherapy for the treatment of
participants with metastatic HER2-positive breast cancer who have progressed on, or are
intolerant to, previous trastuzumab deruxtecan treatment.
A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and
safety of zanidatamab in combination with physician’s choice chemotherapy compared to
trastuzumab in combination with physician’s choice chemotherapy for the treatment of
participants with metastatic HER2-positive breast cancer who have progressed on, or are
intolerant to, previous trastuzumab deruxtecan treatment.
